Published in ACS Chem Neurosci on December 10, 2015
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol (2007) 17.69
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A (1998) 16.04
A structural model for Alzheimer's beta -amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci U S A (2002) 9.55
3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc Natl Acad Sci U S A (2005) 8.60
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell (2005) 8.40
The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry (1993) 7.26
EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol (2008) 5.32
The amyloid state of proteins in human diseases. Cell (2012) 4.53
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov (2011) 4.24
Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat Struct Mol Biol (2010) 3.75
Amyloid formation by globular proteins under native conditions. Nat Chem Biol (2009) 3.72
Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nat Chem (2009) 3.66
Amyloid fibril formation by A beta 16-22, a seven-residue fragment of the Alzheimer's beta-amyloid peptide, and structural characterization by solid state NMR. Biochemistry (2000) 3.65
Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci U S A (2009) 3.06
Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des (2006) 3.04
Small-molecule aggregates inhibit amyloid polymerization. Nat Chem Biol (2008) 2.98
EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci U S A (2010) 2.48
Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med (2006) 2.28
Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio. EMBO J (2010) 2.26
Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem (1995) 2.24
Amyloid beta-protein: monomer structure and early aggregation states of Abeta42 and its Pro19 alloform. J Am Chem Soc (2005) 2.19
Alzheimer's disease: from pathology to therapeutic approaches. Angew Chem Int Ed Engl (2009) 2.12
Cucurbituril homologues and derivatives: new opportunities in supramolecular chemistry. Acc Chem Res (2003) 1.84
Elucidating amyloid beta-protein folding and assembly: A multidisciplinary approach. Acc Chem Res (2006) 1.80
Ion mobility-mass spectrometry reveals a conformational conversion from random assembly to β-sheet in amyloid fibril formation. Nat Chem (2010) 1.53
Toxic fibrillar oligomers of amyloid-β have cross-β structure. Proc Natl Acad Sci U S A (2012) 1.53
Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. J Biol Chem (2009) 1.52
The structural biology of protein aggregation diseases: Fundamental questions and some answers. Acc Chem Res (2006) 1.47
Interaction between A beta(1-42) and A beta(1-40) in Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry (1999) 1.40
Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry (2008) 1.32
Amyloid-beta in Alzheimer disease: the null versus the alternate hypotheses. J Pharmacol Exp Ther (2007) 1.23
ADDLs and the signaling web that leads to Alzheimer's disease. Neuropharmacology (2010) 1.18
Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils. J Am Chem Soc (2013) 1.15
Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy. Acta Neuropathol (2009) 1.10
Disrupting beta-amyloid aggregation for Alzheimer disease treatment. Curr Top Med Chem (2007) 1.08
Rational design of a structural framework with potential use to develop chemical reagents that target and modulate multiple facets of Alzheimer's disease. J Am Chem Soc (2013) 1.07
Screening and classifying small-molecule inhibitors of amyloid formation using ion mobility spectrometry-mass spectrometry. Nat Chem (2014) 1.05
Familial Alzheimer's disease mutations differentially alter amyloid β-protein oligomerization. ACS Chem Neurosci (2012) 1.05
Solution structure of amyloid beta-peptide (25-35) in different media. J Med Chem (2004) 1.04
Design strategies for anti-amyloid agents. Curr Opin Struct Biol (2003) 1.02
Aβ(39-42) modulates Aβ oligomerization but not fibril formation. Biochemistry (2011) 1.01
Structural diversity of dimers of the Alzheimer amyloid-beta(25-35) peptide and polymorphism of the resulting fibrils. Phys Chem Chem Phys (2010) 1.01
Strategies for the inhibition of protein aggregation in human diseases. Chembiochem (2010) 0.98
Ion mobility spectrometry reveals the mechanism of amyloid formation of Aβ(25-35) and its modulation by inhibitors at the molecular level: epigallocatechin gallate and scyllo-inositol. J Am Chem Soc (2013) 0.97
Z-Phe-Ala-diazomethylketone (PADK) disrupts and remodels early oligomer states of the Alzheimer disease Aβ42 protein. J Biol Chem (2012) 0.94
Three-dimensional structures of the amyloid beta peptide (25-35) in membrane-mimicking environment. Biochemistry (1996) 0.93
Interactions of Aβ25-35 β-barrel-like oligomers with anionic lipid bilayer and resulting membrane leakage: an all-atom molecular dynamics study. J Phys Chem B (2010) 0.92
Role of β-hairpin formation in aggregation: the self-assembly of the amyloid-β(25-35) peptide. Biophys J (2012) 0.91
Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanisms. ChemMedChem (2012) 0.89
Probing cucurbituril assemblies in water with TEMPO-like nitroxides: a trinitroxide supraradical with spin-spin interactions. J Am Chem Soc (2009) 0.86
Supramolecular inhibition of amyloid fibrillation by cucurbit[7]uril. Angew Chem Int Ed Engl (2014) 0.86
Molecular basis for preventing α-synuclein aggregation by a molecular tweezer. J Biol Chem (2014) 0.85
Amyloid β-protein assembly: The effect of molecular tweezers CLR01 and CLR03. J Phys Chem B (2015) 0.84
Disordered versus fibril-like amyloid β (25-35) dimers in water: structure and thermodynamics. J Phys Chem B (2010) 0.81
Factors that drive peptide assembly and fibril formation: experimental and theoretical analysis of Sup35 NNQQNY mutants. J Phys Chem B (2013) 0.81
Disrupting self-assembly and toxicity of amyloidogenic protein oligomers by "molecular tweezers" - from the test tube to animal models. Curr Pharm Des (2014) 0.81
Deciphering the specific high-affinity binding of cucurbit[7]uril to amino acids in water. J Phys Chem B (2015) 0.81
General amyloid inhibitors? A critical examination of the inhibition of IAPP amyloid formation by inositol stereoisomers. PLoS One (2014) 0.79
Molecular tweezers inhibit islet amyloid polypeptide assembly and toxicity by a new mechanism. ACS Chem Biol (2015) 0.79
Interactions between amyloid-β and Tau fragments promote aberrant aggregates: implications for amyloid toxicity. J Phys Chem B (2014) 0.78
Amyloid-β-neuropeptide interactions assessed by ion mobility-mass spectrometry. Phys Chem Chem Phys (2013) 0.78
Structural determination of Abeta25-35 micelles by molecular dynamics simulations. Biophys J (2010) 0.78
IAPP aggregation and cellular toxicity are inhibited by 1,2,3,4,6-penta-O-galloyl-β-D-glucose. Amyloid (2013) 0.77